DMARD gets PBS listing
Certolizumab pegol, a monoclonal antibody to tumour necrosis factor alpha, has received a PBS listing for adults with active ankylosing spondylitis (AS) and an intolerance or inadequate response to NSAIDs.
Marketed as Cimzia in Australia, the drug received TGA approval for AS as well as active psoriatic arthritis in May and is already subsidised for patients with severe rheumatoid arthritis.
It is sold as a pack of two 1mL pre-filled syringes with a maximum consumer price of $39.90.
Rheumatologist Professor Matthew Brown of the University of Queensland and Princess Alexandra Hospital welcomed the